Time to castration resistance is an independent predictor of castration-resistant prostate cancer survival

Anticancer Research

Volumn 31, Issue 4, 2011, Pages 1475-1482

  Bournakis, Evangelos ^a   Efstathiou, Eleni ^a,b   Varkaris, Andreas ^a   Wen, Sijin ^b   Chrisofos, Michael ^a   Deliveliotis, Charalambos ^a   Alamanis, Christos ^a   Anastasiou, Ioannis ^a   Constantinides, Constantine ^a   Bamias, Aristotelis ^a   Dimopoulos, Meletios A ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Advanced prostate cancer; Castrate resistant prostate cancer; Chemotherapy; Predictors of survival; Time to castration resistance

Indexed keywords

ALKALINE PHOSPHATASE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE; ETOPOSIDE; HEMOGLOBIN; KETOCONAZOLE; LACTATE DEHYDROGENASE; MITOXANTRONE; NAVELBINE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER SURVIVAL; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DATA BASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERFORMANCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RETROSPECTIVE STUDY; WEIGHT REDUCTION;

AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PAIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 79956136146     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15): 1502-1512, 2004. (Pubitemid 39315317)
2. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr., Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D and Crawford ED: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351(15): 1513-1520, 2004. (Pubitemid 39315318)
3. Sartor AO, Oudard S, Ozguroglu M, Hansen S, Machiels JH, Shen L, Gupta S and De Bono JS: Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC). Abstract 9A, ASCO 2010.
4. Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C, Dearnaley D, Swennenhuis JF, Terstappen LW, Lee G, Kheoh T, Molina A, Ryan CJ, Small E, Scher HI and de Bono JS: Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 28(9): 1489-1495, 2010.
5. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL; Prostate Cancer Foundation/Department of Defense Prostate Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Cancer Clinical Trials Consortium. Lancet 375(9724): 1437-1446, 2010.
6. Bamias A, Bozas G, Antoniou N, Poulias I, Katsifotis H, Skolarikos A, Mitropoulos D, Alamanis C, Alivizatos G, Deliveliotis H and Dimopoulos MA: Prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience. Eur Urol 53(2): 323-331, 2008.
7. Berry WR, Laszlo J, Cox E, Walker A and Paulson D: Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate. Cancer 44: 763-775, 1979. (Pubitemid 10233792)
8. Emrich LJ, Priore RL, Murphy GP and Brady MF: Prognostic factors in patients with advanced stage prostate cancer. Cancer Res 45: 5173-5179, 1985. (Pubitemid 16236210)
9. Thall PF, Logothetis C, Pagliaro LC, Wen S, Brown MA, Williams D and Millikan RE: Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. J Natl Cancer Inst 99(21): 1613-1622, 2007.
10. Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN Jr., Jones JA, Taplin ME, Burch PA, Kohli M, Benson MC, Small EJ, Raghavan D and Crawford ED: Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 98(8): 516-521, 2006. (Pubitemid 43898814)
11. Drake CG and Antonarakis ES: Update: immunological strategies for prostate cancer. Curr Urol Rep 11(3): 202-207, 2010.
12. Kelly WK, Halabi S, Carducci MA, George DJ, Mahoney JF, Stadler WM, Morris MJ, Kantoff P, Monk III JP and Small EJ: A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. J Clin Oncol 28: 7s (suppl; abstr LBA4511), 2010.
13. Halabi S, Vogelzang NJ, Kornblith AB, Ou SS, Kantoff PW, Dawson NA and Small EJ: Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol 26(15): 2544-2549, 2008.
14. Berthold DR, Pond G and De Wit R: Association of pain and quality of life (QOL) response with PSA response and survival of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) treated with docetaxel or mitoxantrone in the TAX-327 study. J Clin Oncol 24: 221s (suppl, abstr 4516), 2006.
15. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF and Eisenberger M: A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 75: 6396-6403, 2007. (Pubitemid 350075029)
16. Sabbatini P, Larson SM, Kremer A, Zhang ZF, Sun M, Yeung H, Imbriaco M, Horak I, Conolly M, Ding C, Ouyang P, Kelly WK and Scher HI: Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 17: 948-957, 1999. (Pubitemid 29109328)
17. Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S and Moinuddin M: Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61: 195-202, 1988. (Pubitemid 18023133)
18. Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, Mac Vicar G and Raghavan D: Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from the Southwest Oncology Group trial 9346 (INT-0162). J Clin Oncol 24: 3984-3990, 2006. (Pubitemid 46630748)
19. Stewart AJ, Scher HI, Chen M-H, McLeod DG, Carroll PR, Moul JW and D'Amico AV: Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 23: 6556-6560, 2005. (Pubitemid 46190248)